Product Reports Resources Pricing Login Book a demo
Michael Dybbs
Person deep dive

Michael Dybbs

#47 2026 Strebulaev–Jackson Venture Ranking, emerging firms

Mike Dybbs is a partner at Samsara BioCapital, the Palo Alto life sciences investor, and has been there since its first fund in 2017. Before that he sat on the board of Principia Biopharma for New Leaf Venture Partners; Sanofi bought the company in 2020.

Education
University of California, Berkeley, Harvard University

Track record

Investments Michael Dybbs is best known for, with what became of them.

Samsara BioCapital

FirmSamsara BioCapital
Founded2016
Based inPalo Alto
FundsRaised $260.6M toward a $300M first fund by 2018, per an SEC filing
FocusLife sciences, from seed rounds to public equities

Career

  1. 2009Joined New Leaf Venture Partners after working as a principal at Boston Consulting Group; he became a partner and sat on the boards of Principia, Versartis and Dimension Therapeutics.
  2. 2017Joined Samsara BioCapital as a partner when the firm launched its first fund.
  3. 2018Joined the board of Sutro Biopharma, which listed on Nasdaq the same year.

Sources: Biocom: Mike Dybbs, Samsara BioCapital · Sutro Biopharma: Michael Dybbs · Venture Capital Journal: Samsara BioCapital raises $260.6M · Dealroom: Mike Dybbs. Rank: 2026 Strebulaev–Jackson Venture Ranking.

Currently

Active roles, board seats and partnerships.

Samsara BioCapital
Partner · 2017 – present
Versartis
Board of Director
$330M valuation (2014)
→

Work history

Past roles by Dealroom records.

Education

University of California, Berkeley
PhD · 1999 – 2005
Harvard University
1993 – 1997
← All people